IP Library Granted Patent US 8,241,879
Granted Patent B2
US 8,241,879 · App. 13/245,777 · Granted Aug 14, 2012

Biological methods for preparing adipic acid

Assignee: Verdezyne, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,241,879
App. No.
13/245,777
Granted
Aug 14, 2012
Kind
B2
Abstract

The technology relates in part to biological methods for producing adipic acid and engineered microorganisms capable of such production.

Claims (23)

1. A method for producing adipic acid, comprising:

(a) contacting a Candida yeast with a feedstock comprising a mixture of fatty acids from a vegetable oil, wherein the Candida yeast comprises genetic alterations that:

(i) reduce or eliminate the amount of a POX4 polypeptide, thereby partially blocking beta oxidation activity,

(ii) add or increase a CYP52A15, CYP52A16, or CYP52A19 monooxygenase activity, and

(iii) add or increase a monooxygenase reductase activity; and

(b) culturing the Candida yeast under conditions in which adipic acid is produced.

2. The method of claim 1 , wherein the vegetable oil is a palm oil.

3. The method of claim 1 , wherein the vegetable oil is a soybean oil.

4. The method of claim 1 , wherein the vegetable oil is a fatty acid soap stock.

5. The method of claim 1 , wherein the Candida yeast is a genetically modified ATCC20336 yeast.

6. The method of claim 1 , wherein the genetic alteration that adds or increases the monooxygenase reductase activity comprises (i) increasing the copy number of a CPRA coding sequence, or (ii) modifying or adding a promoter in operable connection with a CPRA coding sequence.

7. The method of claim 1 , wherein the genetic alteration that adds or increases the monooxygenase reductase activity comprises (i) increasing the copy number of a CPRB coding sequence, or (ii) modifying or adding a promoter in operable connection with a CPRB coding sequence.

8. The method of claim 1 , wherein the genetic alteration that adds or increases the monooxygenase reductase activity comprises (i) increasing the copy number of a CPRA coding sequence, or (ii) modifying or adding a promoter in operable connection with a CPRA coding sequence; and (iii) increasing the copy number of a CPRB coding sequence, or (iv) modifying or adding a promoter in operable connection with a CPRB coding sequence.

9. The method of claim 1 , wherein the Candida yeast comprises a genetic alteration that adds or increases a CYP52A15 monooxygenase activity.

10. The method of claim 9 , wherein the genetic alteration increases the copy number of a polynucleotide that encodes a polypeptide having the CYP52A15 monooxygenase activity.

11. The method of claim 9 , wherein the genetic alteration comprises modifying or adding a promoter in operable connection with a polynucleotide that encodes a polypeptide having the CYP52A15 monooxygenase activity.

12. The method of claim 1 , wherein the Candida yeast comprises a genetic alteration that adds or increases a CYP52A16 monooxygenase activity.

13. The method of claim 12 , wherein the genetic alteration increases the copy number of a polynucleotide that encodes a polypeptide having the CYP52A16 monooxygenase activity.

14. The method of claim 12 , wherein the genetic alteration comprises modifying or adding a promoter in operable connection with a polynucleotide that encodes a polypeptide having the CYP52A16 monooxygenase activity.

15. The method of claim 1 , wherein the Candida yeast comprises a genetic alteration that adds or increases a CYP52A19 monooxygenase activity.

16. The method of claim 15 , wherein the genetic alteration increases the copy number of a polynucleotide that encodes a polypeptide having the CYP52A19 monooxygenase activity.

17. The method of claim 15 , wherein the genetic alteration comprises modifying or adding a promoter in operable connection with a polynucleotide that encodes a polypeptide having the CYP52A19 monooxygenase activity.

18. The method of claim 1 , wherein the adipic acid is produced at a level of at least 0.4 grams per liter of culture medium.

Assignments (4)
CORRECTIVE ASSIGNMENT TO CORRECT THE ADDRESS OF THE ASSIGNEE PREVIOUSLY RECORDED ON REEL 050361 FRAME 0690. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Feb 4, 2020
From: VERDEZYNE (ABC) LLC
To: RADICI CHIMICA S.P.A.
Reel/Frame 051794/0070 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 29, 2019
From: VERDEZYNE (ABC) LLC
To: RADICI CHIMICA S.P.A.
Reel/Frame 050361/0690 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 29, 2019
From: VERDEZYNE, INC.
To: VERDEZYNE (ABC) LLC
Reel/Frame 048741/0925 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 21, 2011
From: PICATAGGIO, STEPHEN; BEARDSLEE, TOM
To: VERDEZYNE, INC.
Reel/Frame 027102/0985 →
Continuity (3)
Continuation PCTUS2010040837 · Jul 1, 2010
Provisional Application 61222902 · Jul 2, 2009
Related Publication 20120021474A1 · Jan 26, 2012